Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more ...
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and ...
Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader ...
Chronic lymphocytic leukemia has long been one of the most stubborn targets for chimeric antigen receptor T cell therapy, a ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, ...
Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the ...
India Today on MSN
From pharmacy to laboratory: India's leap into drug discovery
India's pharmaceutical industry is moving beyond generics towards novel drug discovery, with AI, biotech start-ups and advanced therapies reshaping the landscape. But stronger funding, ...
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...
Why Is CRBU Stock Falling Today? Caribou Biosciences Falls After Halting CAR-T Programs and Exploring Strategic Alternatives ...
For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...
Imugene Reports New Responses With Azercabtagene Zapreleucel Plus BTK Inhibitor in Phase 1b Blood Cancer Trial / allogeneic ...
Spread the loveImagine a future where cancer treatments are not just effective, but hyper-personalized, designed with such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results